Fisetin vs Quercetin: Which Senolytic?

Short answer: on the current evidence, fisetin is the stronger stand-alone senolytic and quercetin is the better-evidenced everyday flavonol. Fisetin was the most potent of ten flavonoids screened for senolytic activity in a landmark 2018 study and is the one being trialled on its own in humans. Quercetin is a weak senolytic by itself — its senolytic reputation comes almost entirely from being paired with the prescription drug dasatinib — but it has far more human data for blood pressure, metabolic markers and general safety. If you want to target senescent cells, fisetin is the more logical choice. If you want a broadly useful daily flavonol, quercetin is.

For where senolytics sit among the alternatives, start with our pillar guide to longevity supplements and browse the full anti-ageing and longevity range.

That is the headline. The detail matters more, because the gap between what senolytics do in mice and what they have been shown to do in people is still very wide. Below we work through the chemistry, the actual trial data on both sides, dosing protocols, bioavailability, safety and interactions, and a practical decision framework — with the limitations stated plainly rather than buried.

Table of contents

Fisetin vs quercetin at a glance

Both are flavonols — a subclass of the flavonoid polyphenols — and they are structurally almost identical. Their evidence bases, however, point in different directions.

What a senolytic actually is

The senescent cell problem

When a cell is damaged beyond safe repair — by DNA damage, oxidative stress, telomere shortening or oncogene activation — it can enter a state called cellular senescence. It stops dividing permanently but does not die. In a young body these cells are cleared efficiently by the immune system. With age, both the production rate rises and the clearance rate falls, so they accumulate.

The problem is not that they sit there inertly. Senescent cells secrete a cocktail of inflammatory cytokines, chemokines, growth factors and proteases known as the senescence-associated secretory phenotype (SASP). SASP factors drive chronic low-grade inflammation, degrade the surrounding tissue matrix, and can push neighbouring healthy cells into senescence themselves. Cellular senescence is one of the recognised hallmarks of ageing, and animal work has shown that removing these cells — genetically or pharmacologically — improves multiple age-related outcomes.

How senolytics work

Senescent cells survive their own toxic secretions by upregulating anti-apoptotic pathways, often called senescent cell anti-apoptotic pathways (SCAPs). These include members of the BCL-2 protein family (BCL-2, BCL-xL, BCL-w), the PI3K/AKT axis, and p53/p21-related networks. Senolytics work by transiently disabling those survival pathways, so that the senescent cell's own pro-apoptotic environment finishes the job. Healthy cells, which are not relying on those pathways to stay alive, are largely spared.

This mechanism explains a crucial practical point that trips people up: senolytics are not designed to be taken continuously. Because the cell is killed rather than merely suppressed, the drug does not need to remain present. Researchers call this a "hit-and-run" approach — short, high-dose bursts with long gaps in between. That dosing logic is very different from the daily-dose model most people apply to supplements, and it is one of the clearest differences between how fisetin and quercetin are actually used.

The chemistry: one hydroxyl group apart

Fisetin is 3,3′,4′,7-tetrahydroxyflavone. Quercetin is 3,3′,4′,5,7-pentahydroxyflavone. The only difference is a single hydroxyl (–OH) group at position 5 on the A ring, which quercetin has and fisetin does not. Fisetin is occasionally listed under the synonym 5-deoxyquercetin for exactly this reason.

Why one hydroxyl changes so much

A single –OH group sounds trivial. In flavonoid pharmacology it is not. The hydroxylation pattern determines lipophilicity, how strongly the molecule binds to particular protein targets, which phase II conjugation enzymes act on it, and how readily it crosses membranes. Losing the 5-OH makes fisetin somewhat more lipophilic than quercetin, which is part of why fisetin is discussed in the context of crossing the blood–brain barrier and why it behaves differently in senolytic screens despite the near-identical scaffold.

It also means the two compounds are not interchangeable. Assuming that a quercetin supplement will "do the same thing" as fisetin because they look alike is the single most common error in this area. The screening data below shows exactly why that assumption fails.

Where they come from in food

Strawberries contain more fisetin than any other commonly eaten food, at approximately 160 micrograms per gram of fresh fruit. Apples, persimmons, grapes, onions and cucumbers contain smaller amounts. Average dietary intake in a typical Western diet is estimated at around 0.4 mg per day.

Put that next to the doses used in research and the gap becomes obvious. A 150 g punnet of strawberries supplies roughly 24 mg of fisetin. Human senolytic trials use 20 mg/kg/day — around 1,400 mg for a 70 kg adult. You would need to eat several kilograms of strawberries a day to approach that. This is not an argument against eating strawberries; it is simply the reason concentrated supplements exist for this specific purpose.

Quercetin is far more abundant in the ordinary diet. Onions, capers, apples, kale, broccoli, berries, tea and red wine all contribute. Depending on eating patterns, habitual intake typically lands somewhere between a few milligrams and several tens of milligrams a day — still an order of magnitude below supplemental doses, but a much larger baseline exposure than fisetin.

The senolytic evidence for fisetin

The 2018 screening study that started it

The pivotal paper is Yousefzadeh and colleagues, published in EBioMedicine in 2018 by a team spanning the Scripps Research Institute, the University of Minnesota and the Mayo Clinic. The researchers screened a panel of flavonoid polyphenols for senolytic activity in senescent mouse and human fibroblasts. Of the ten flavonoids tested, fisetin was the most potent senolytic. That single finding is the origin of essentially every "fisetin is the best natural senolytic" claim you will read online.

The same paper then took fisetin into animals. Acute or intermittent treatment of progeroid mice and old wild-type mice reduced senescence markers across multiple tissues — a pattern the authors described as consistent with a hit-and-run senolytic mechanism. In human adipose tissue explants, fisetin reduced senescent cell markers, which is what made the finding translationally interesting rather than a purely rodent curiosity.

Cell-type specificity: an important caveat

An earlier 2017 paper from Zhu and colleagues at the Mayo Clinic reported something that is often left out of supplement marketing. Fisetin selectively induced apoptosis in senescent human umbilical vein endothelial cells (HUVECs) — but it was not senolytic in senescent IMR90 human lung fibroblasts or in primary human preadipocytes.

In other words, fisetin does not clear every senescent cell in every tissue. Senolytic activity is cell-type specific, and the 2018 study similarly found fisetin reduced senescence only in a subset of cells within adipose tissue. This is a genuine biological limitation, not a formulation problem, and it is one of the reasons researchers are interested in combinations rather than single agents.

The mouse lifespan result

The headline finding from the 2018 paper is that chronic administration of fisetin to wild-type mice started late in life improved tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan. Late-life initiation matters: it suggests benefit does not depend on lifelong dosing.

What the mouse data does not show

It does not show that fisetin extends human lifespan. It does not establish an effective human dose. And mouse lifespan studies have a long history of failing to replicate in people. Doses used in the rodent work were high on a body-weight basis, and mouse flavonoid metabolism differs from human metabolism. Treating this as proof of human benefit is exactly the kind of overreach that has damaged the credibility of the wider field — a theme we cover in longevity supplements that don't work.

Where human fisetin trials stand

Fisetin is being tested in humans across a range of conditions: frailty in older adults, knee osteoarthritis, chronic kidney disease, skeletal health, physical function in breast cancer survivors, and inflammatory complications of infection. Registered protocols consistently use the same design — oral fisetin at 20 mg/kg/day for two to three consecutive days, repeated in cycles.

The honest summary of where translation currently stands comes from a 2025 Mayo Clinic overview by Sundeep Khosla: at the time of writing there were roughly 26 registered studies of senolytics and 32 of fisetin, but only nine published clinical trials of senolytics, of which just two included a control group. Initial findings suggest possible biological efficacy for dasatinib plus quercetin on healthspan biomarkers, with no significant safety signals so far. That is a very early-stage evidence base by any medical standard.

The senolytic evidence for quercetin

Quercetin alone is a weak senolytic

Quercetin's place in senolytic history is genuine but frequently misrepresented. It was part of the very first senolytic combination identified — dasatinib plus quercetin (D+Q) — and it appears on every list of "reported senolytics" in the literature. What is usually omitted is that quercetin's contribution in that pairing is partial and complementary. Dasatinib preferentially clears senescent preadipocytes; quercetin preferentially clears senescent endothelial cells. Neither is broadly effective alone; together they cover more cell types.

This is why the 2018 fisetin screen was performed in the first place. The stated goal of that study was to find flavonoids with more potent senolytic activity than quercetin. It found one.

The first-in-human senolytic trial

The first published human senolytic study, by Justice and colleagues in EBioMedicine in 2019, was an open-label pilot in 14 patients with idiopathic pulmonary fibrosis. Participants took dasatinib 100 mg/day plus quercetin 1,250 mg/day (as a quercetin phytosome), three days per week for three weeks. The primary endpoints were feasibility measures — retention and completion rates — not efficacy. Physical function measures including six-minute walk distance and gait speed improved, and the regimen was tolerable.

It is important to read that result for what it is: a 14-person, open-label, uncontrolled feasibility study. It demonstrated that the approach could be run in patients. It did not demonstrate efficacy. A subsequent single-blind, placebo-controlled pilot in the same condition again reported that intermittent D+Q was feasible and tolerable, while flagging areas needing closer safety and symptom monitoring in future trials.

The randomised trial that missed its primary endpoint

The most informative quercetin senolytic data comes from a phase 2 randomised controlled trial published in Nature Medicine in 2024 by Farr, Khosla and colleagues. Sixty postmenopausal women received intermittent D+Q or control over 20 weeks, with bone turnover markers as the outcome.

The primary endpoint was negative. The change in the bone resorption marker CTx at 20 weeks did not differ between groups. The bone formation marker P1NP rose significantly relative to control at 2 weeks (+16%) and 4 weeks (+16%), but the difference had disappeared by 20 weeks. No serious adverse events occurred.

An exploratory analysis is where it gets interesting. In the subgroup of women with the highest senescent cell burden — the top tertile for T-cell p16 mRNA — D+Q increased P1NP by 34%, reduced CTx by 11% at 2 weeks, and increased radius bone mineral density by 2.7% at 20 weeks. That is a hypothesis-generating signal, not a confirmed effect, but it points to something clinically significant: senolytics may only benefit people who actually have a high senescent cell burden. Since there is currently no accessible way to measure that at home, this is a real limitation on rational self-prescribing.

Head-to-head: which is the better senolytic?

If the question is strictly "which compound, taken on its own, is the better senolytic?", the answer from the published literature is fisetin. It outperformed quercetin and eight other flavonoids in a direct head-to-head screen, it is the one with stand-alone mouse lifespan data, and it is the one being trialled as a single agent in humans.

If the question is "which senolytic protocol has the most human evidence behind it?", the answer flips to quercetin — but only in combination with dasatinib, a prescription tyrosine kinase inhibitor licensed for chronic myeloid leukaemia. That is a fundamentally different intervention from a quercetin capsule, and it is not something you can replicate over the counter. Dasatinib is a potent drug with meaningful side effects, and it is not available for this purpose in the UK outside a clinical trial.

So the practical conclusion is narrower than the headlines suggest: for someone choosing a supplement, fisetin is the better senolytic candidate, and quercetin is the better general-purpose flavonol. Neither is a proven senolytic therapy in humans on its own.

Beyond senolysis: where quercetin pulls ahead

Judging quercetin only as a senolytic undersells it. It has a considerably larger body of human outcome data than fisetin — it just is not about senescent cells.

Blood pressure

A systematic review and meta-analysis published in the Journal of the American Heart Association pooled seven randomised placebo-controlled trials (nine treatment arms, 587 participants). Quercetin supplementation significantly reduced systolic blood pressure by 3.04 mmHg and diastolic blood pressure by 2.63 mmHg. In a dose subgroup analysis, the effect was seen at doses of 500 mg/day or above (systolic −4.45 mmHg) but not below 500 mg/day.

Metabolic markers

A 2024 dose–response meta-analysis of 20 randomised controlled trials involving 1,164 participants examined quercetin's effect on metabolic syndrome components. It found significant reductions in fasting blood glucose (−1.03 mg/dL) and systolic blood pressure (−1.96 mmHg). These are modest effects, and modest is the honest word for them — but they are replicated across randomised trials, which is more than can be said for most longevity supplements.

Where fisetin's non-senolytic evidence sits

Fisetin has substantial preclinical literature on anti-inflammatory, antioxidant and neuroprotective activity, including work on the PI3K/AKT and mTOR pathways. What it lacks is a comparable body of randomised human outcome data. Reviews of fisetin as a senotherapeutic agent are consistent on this point: the preclinical case is strong, human data remain limited, and poor bioavailability with rapid metabolism is a significant obstacle to clinical translation.

Bioavailability and formulation

This is where a lot of money gets wasted. Both flavonols are poorly water-soluble and both undergo rapid phase II metabolism — glucuronidation and sulfation in the intestinal wall and liver — so a large fraction of what you swallow never reaches tissues as the parent compound. What circulates is a mixture of conjugated metabolites whose biological activity is not identical to the parent molecule.

What actually improves absorption

• Take with dietary fat. Both compounds are lipophilic. Taking them with a meal containing fat meaningfully improves absorption compared with a fat-free meal or an empty stomach. See our guide on which supplements to take on an empty stomach and the supplement timing chart.
• Phytosome and liposomal delivery. The IPF trials used a quercetin phytosome (a phospholipid complex) rather than raw quercetin powder, specifically because absorption of the raw material is so poor. The same logic applies to liposomal fisetin. Our article on liposomal delivery systems explains the underlying principle.
• Avoid the cheapest raw powders. Unformulated flavonol powder at a bargain price is usually poor value, because the limiting factor is not the milligrams on the label — it is how many of them reach circulation.

Dosing protocols: pulsed vs daily

This is the most practically useful distinction in the whole fisetin vs quercetin comparison, and the one most often got wrong.

How fisetin is dosed in research

Registered human trials use oral fisetin at 20 mg/kg/day for two to three consecutive days, repeated at intervals — for example on days 1–3 of a 14-day cycle for several cycles. For a 70 kg adult that is roughly 1,400 mg on each dosing day. Commercial supplements are typically sold at 100–500 mg per capsule, so trial-level dosing would require multiple capsules and is well above what most labels recommend.

This is important context rather than a recommendation. Trial doses are administered under medical supervision, with monitoring and exclusion criteria. Taking gram-level flavonoid doses unsupervised is not the same activity, and the long-term safety of repeated high-dose pulsing outside a trial has not been established.

How quercetin is dosed

For its non-senolytic benefits, quercetin is taken continuously — commonly 500–1,000 mg per day, since the blood-pressure meta-analysis found effects at 500 mg/day and above but not below. The Linus Pauling Institute notes that oral supplementation with quercetin glycosides at 3 mg to 1,000 mg per day for up to three months has not produced significant adverse effects in clinical studies.

Can you take fisetin and quercetin together?

There is no published randomised human trial of the fisetin plus quercetin combination, so any claim of synergy is extrapolation rather than evidence. The theoretical rationale is reasonable — the two clear different senescent cell types, so coverage might be broader together — but theoretical rationale is exactly what has failed repeatedly in this field.

What can be said sensibly is this: both compete for the same phase II metabolic enzymes, so taking large doses of both simultaneously may not deliver proportionally more of either. Both also inhibit the same drug-metabolising enzymes, so combined use compounds interaction risk in anyone on medication. If you are taking both, the more common approach is continuous quercetin with intermittent fisetin pulses, which keeps the two dosing logics intact. Our guide on which supplements can be taken together covers the general principles, and how to start longevity supplements covers sequencing.

Safety, side effects and drug interactions

This section matters more than any efficacy discussion, because the interaction profile of these compounds is genuinely clinically relevant.

Quercetin

Quercetin is well tolerated at typical supplemental doses in short-term studies. The concern is not toxicity — it is enzyme inhibition. Quercetin inhibits several cytochrome P450 enzymes (including CYP3A4, CYP2C9 and CYP2C8) and modulates P-glycoprotein, the efflux transporter that controls how much of many drugs is absorbed and retained. The Linus Pauling Institute specifically flags that high or supplemental flavonoid intakes could increase the bioavailability, and therefore the toxicity, of drugs that are P-glycoprotein substrates.

Drug classes where this matters include anticoagulants (particularly warfarin, which has a narrow therapeutic index), digoxin, ciclosporin and other immunosuppressants, certain statins, quinolone antibiotics, calcium channel blockers, some antifungals and antiretrovirals, and several chemotherapy agents. Clinical trial protocols using quercetin routinely list these as cautions.

Fisetin

Fisetin has a shorter human safety record. Trial investigators have reported no severe or serious adverse events at the pulsed doses used, but those are small studies over short periods. Long-term safety of repeated high-dose fisetin has not been established, and as a flavonol it shares quercetin's general potential to interact with drug-metabolising enzymes.

Reported side effects

• Common and mild: nausea, stomach discomfort, loose stools — most often at higher doses or when taken without food.
• Occasional: headache, tingling in the extremities (reported with high-dose quercetin).
• Requires medical attention: unusual bruising or bleeding, unexplained muscle pain or weakness, jaundice, or any new symptom after starting a supplement alongside prescription medication.

Buying fisetin and quercetin in the UK

In Great Britain both are sold as food supplements, not medicines. Neither has an authorised EFSA health claim, which means legally compliant products cannot claim to treat, prevent or cure anything — and the regulatory status of a specific extract can depend on its botanical source and extraction method under retained novel food rules. That is a manufacturing and compliance question rather than a consumer one, but it is a useful signal: brands that understand it tend to run better quality systems generally.

What to check before you buy

• A batch-specific certificate of analysis. Not a generic PDF for the ingredient — one that matches the batch number on your bottle. Our certificate of analysis guide explains what to look for.
• Independent third-party testing for identity, potency, heavy metals and microbial contamination. See third-party tested supplements.
• Stated extract source and standardisation percentage — for example fisetin from Cotinus coggygria standardised to 98%.
• Formulation, not just dose. Phytosome or liposomal forms address the actual bottleneck.
• A short excipient list. Our guide to supplement fillers covers which ones are worth avoiding.

On price: unusually cheap flavonol powder is a warning sign, for the reasons set out in why longevity supplements are expensive. If you are budgeting across a whole regimen, what a longevity stack actually costs in the UK is the more useful frame than per-bottle price.

How they fit into a wider longevity stack

Senolytics address one hallmark of ageing. They do nothing for NAD+ decline, mitochondrial dysfunction, autophagy, or the other mechanisms running in parallel. A senolytic taken in isolation is a narrow intervention.

Most structured regimens treat senolytics as an intermittent add-on to a continuous foundation. That foundation usually centres on NAD+ precursors — which is why we maintain a dedicated pillar guide on NMN benefits, side effects and dosage, alongside our NAD supplement guide. If you are building from scratch, how to build a longevity stack and the minimal effective stack are the practical starting points, and you can compare tested options in the Welzo NMN and longevity collection — including NMN Pro 1000, our highest-strength third-party-tested NMN.

Related comparisons worth reading alongside this one: spermidine vs NMN (autophagy versus NAD+), resveratrol vs pterostilbene (another near-identical polyphenol pair with very different bioavailability), urolithin A vs NMN (mitophagy), and autophagy explained. If you are wondering how long any of this takes to show up, see how long supplements take to work and how biological age is measured.

The verdict

Choose fisetin if your specific interest is senescent cell clearance. It is the compound with the strongest preclinical senolytic credentials, the only one of the two with stand-alone mammalian lifespan data, and the one being trialled as a single agent. Accept that human evidence is still early, and use the intermittent dosing pattern the research actually uses rather than a daily habit.

Choose quercetin if you want a daily flavonol with replicated randomised human data behind it. Its blood-pressure and metabolic effects are modest but real, its safety record at supplemental doses is longer, and it is cheaper. Do not buy it expecting a senolytic effect on its own — that is not what the evidence supports.

Choose neither, for now, if you have not yet addressed sleep, resistance training, cardiovascular fitness and diet quality. The effect sizes available from those interventions dwarf anything demonstrated for either flavonol in humans, and a supplement layered on top of an unstable foundation is the least efficient move available. Zone 2 training and what the Blue Zones data actually shows are better places to spend your first effort.

Frequently asked questions

Is fisetin better than quercetin?

As a stand-alone senolytic, yes — fisetin was the most potent of ten flavonoids screened for senolytic activity and is the one with mouse lifespan data on its own. As a general daily supplement, quercetin has more randomised human evidence, particularly for blood pressure and metabolic markers. "Better" depends entirely on which of those two goals you have.

Can I take fisetin and quercetin together?

There is no randomised human trial of the combination, so any synergy claim is theoretical. If you do take both, the usual approach is continuous quercetin plus intermittent fisetin pulses. Because both inhibit the same drug-metabolising enzymes, combining them increases interaction risk if you take any prescription medication — check with a pharmacist first.

Is quercetin actually a senolytic?

Only weakly on its own. Quercetin appears in the senolytic literature because it was half of the original dasatinib plus quercetin combination. In that pairing, dasatinib and quercetin clear different senescent cell types, and the combination is what produced the effects. A quercetin capsule taken alone is not equivalent to D+Q.

How much fisetin should I take?

Human trials use 20 mg/kg/day for two to three consecutive days, repeated in cycles — roughly 1,400 mg per dosing day for a 70 kg adult, under medical supervision. Commercial products typically supply 100–500 mg per capsule and their label directions are lower than trial doses. Follow the product label and discuss higher intakes with a clinician rather than self-escalating.

Should fisetin be taken every day or in pulses?

The research model is pulsed. Senolytics kill the target cell rather than suppressing it, so the compound does not need to remain in circulation — this is the "hit-and-run" principle described in the 2018 fisetin study. Daily fisetin does not match how the compound has been studied for senolytic purposes.

Can I get enough fisetin from strawberries?

No. Strawberries are the richest dietary source at around 160 µg per gram, so a 150 g punnet supplies roughly 24 mg. Trial protocols use doses around fifty times that on a dosing day. Strawberries remain worth eating — just not as a substitute for a studied senolytic dose.

Does quercetin lower blood pressure?

A meta-analysis of seven randomised placebo-controlled trials found quercetin reduced systolic blood pressure by about 3 mmHg and diastolic by about 2.6 mmHg, with the effect concentrated at doses of 500 mg/day and above. That is a modest, real effect — not a replacement for antihypertensive medication.

Are there any proven human anti-ageing effects from either?

Not for ageing itself. A 2025 Mayo Clinic overview noted that despite dozens of registered studies, only nine clinical trials of senolytics had been published and just two included a control group. The one substantial randomised trial of D+Q in postmenopausal women missed its primary endpoint. Early signals exist; proof does not.

What are the side effects of fisetin and quercetin?

Both are generally well tolerated at supplemental doses, with mild gastrointestinal upset and headache the most commonly reported effects. The more important issue is interaction: both inhibit cytochrome P450 enzymes and modulate P-glycoprotein, which can raise or lower blood levels of many prescription drugs including anticoagulants, digoxin, ciclosporin and certain statins.

Which should I buy if I can only afford one?

If you have no specific senolytic objective, quercetin — it is cheaper, has more human outcome data, and is safer to take continuously. If senescent cell clearance is genuinely your goal and you understand the evidence is preclinical-heavy, fisetin in a well-formulated, third-party-tested product used on an intermittent schedule is the more logical purchase. Either way, prioritise formulation quality over milligrams per pound.

References

1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28. https://pubmed.ncbi.nlm.nih.gov/30279143/
2. Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging. 2017;9(3):955–963. https://pmc.ncbi.nlm.nih.gov/articles/PMC5391241/
3. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554–563. https://pubmed.ncbi.nlm.nih.gov/30616998/
4. Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nature Medicine. 2024. https://www.nature.com/articles/s41591-024-03096-2
5. Farr JN, et al. Full text of the phase 2 senolytic bone trial. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11705617/
6. Khosla S. Translating senolytics from mice to humans. Innovation in Aging. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12759346/
7. Nambiar A, Kellogg D, Justice J, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: a phase I, single-blind, randomized, placebo-controlled pilot trial. eBioMedicine. 2023. https://www.sciencedirect.com/science/article/pii/S2352396423000464
8. Serban MC, Sahebkar A, Zanchetti A, et al. Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2016. https://www.ahajournals.org/doi/10.1161/jaha.115.002713
9. Effect of quercetin supplementation on the components of metabolic syndrome in adults: a systematic review and dose–response meta-analysis of randomized controlled trials. Journal of Functional Foods. 2024. https://www.sciencedirect.com/science/article/pii/S1756464624001774
10. Linus Pauling Institute, Oregon State University. Flavonoids — Micronutrient Information Center. https://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/flavonoids
11. Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases. Mechanisms of Ageing and Development. 2024. https://www.sciencedirect.com/science/article/pii/S0047637424000952
12. National Center for Biotechnology Information. PubChem Compound Summary: Fisetin, CID 5281614. https://pubchem.ncbi.nlm.nih.gov/compound/Fisetin
13. ClinicalTrials.gov. Senolytic drugs attenuate osteoarthritis-related articular cartilage degeneration: a clinical trial (NCT04210986). https://clinicaltrials.gov/study/NCT04210986
14. ClinicalTrials.gov. COVID-FISETIN: pilot in SARS-CoV-2 of fisetin to alleviate dysfunction and inflammation (NCT04476953). https://clinicaltrials.gov/study/NCT04476953
15. A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study. PubMed. https://pubmed.ncbi.nlm.nih.gov/41835341/
16. European Commission. Novel Food status catalogue. https://food.ec.europa.eu/food-safety/novel-food/novel-food-status-catalogue_en
17. University of Minnesota Medical School. Researchers have discovered how to slow aging. ScienceDaily, 2018. https://www.sciencedaily.com/releases/2018/10/181002114024.htm